midostaurin (MultiTarget Pharmaceuticals)
Structured Review

Midostaurin, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/midostaurin/pmc07001097-32-0-3
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis"
Article Title: European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
Journal: ESMO Open
doi: 10.1136/esmoopen-2019-000606
Figure Legend Snippet: Molecular structure of midostaurin.
Techniques Used:
Figure Legend Snippet: Key favourable and unfavourable effects for midostaurin in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive (study A2301; cut-off date: 1 April 2015)
Techniques Used: Mutagenesis, Infection
Figure Legend Snippet: Effects table for midostaurin in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL) (study D2201; cut-off date: 1 December 2014)
Techniques Used: Modification
Related Articles
Activation Assay:Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria. Injection:Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria. Inhibition:Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria. Mutagenesis:Article Title: Cardiac complications in a patient affected by systemic mastocytosis and primitive myelofibrosis: A case report Article Snippet: .. The more recent drug approved for the SM‐AHNMD is Article Title: Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1. Article Snippet: Here, we discover an FLT3/CHK1 dual inhibitor (30) that exhibits excellent kinase potency and antiproliferative activity against MV4-11 cells.. Simultaneously, 30 possesses high selectivity over c-Kit enzyme and low hERG inhibitory ability.. Compound 30, meanwhile, overcomes varied resistance in BaF3 cell lines carrying FLT3-TKD and FLT3-ITD mutations. other:Article Title: Effect of flavonoids and CYP3A4 variants on midostaurin metabolism. Article Snippet: The objective of this study was to determine the effect of flavonoids on midostaurin disposition considering coadministration and metabolic enzyme gene polymorphism.. Enzymatic incubation assays were performed in vitro, while in vivo experiments were conducted in Sprague–Dawley rats.. The analytes were determined via UPLC-MS/ MS. We found that myricetin was the most potent among the investigated 10 flavonoids in suppressing the metabolism of midostaurin, with an IC50 at a low μM level. Article Title: Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment Article Snippet: Introduction: Whereas most patients with aggressive hematological malignancies can achieve disease remission after receiving current standard first-line chemotherapies, the prognosis of those with primary refractory disease remains poor.. Conventional salvage chemotherapies are usually unsuccessful, but significant advances have been achieved in precision medicine for these patients in recent years.. Areas covered: This article presents a comprehensive review of current personalized care for patients with primary refractory aggressive hematological malignancies, focusing on acute leukemias and aggressive non-Hodgkin lymphomas. |
